TY - JOUR
T1 - Prolonged immune response evoked by a single subcutaneous injection of microcapsules having a monophasic antigen release
AU - Sah, Hongkee
AU - Chien, Yie W.
PY - 1996
Y1 - 1996
N2 - A model antigen, bovine serum albumin (BSA), was successfully incorporated into microcapsules fabricated from blends of poly(d,l-lactide-co-glycolide) and poly(d,l-lactide). The microcapsules possessed diameters ranging from 10 to 100 μm and exhibited a continuous monophasic release of the protein in-vitro for 3 weeks. They were found to enhance its immunogenicity, thereby potentiating the anti-BSA antibody response following a single subcutaneous injection in mice and rabbits. Enzyme-linked immunosorbent assays demonstrated that the microcapsules provoked high-titre and long-lived immunoglobulin G immune responses over a period of 192 days in mice. When rabbits were immunized by a single subcutaneous injection of BSA-loaded microcapsules, a high level of anti-BSA antibody was still present in the sera obtained at 17 weeks post-injection. The immunization protocol using the BSA-loaded microcapsules was superior to that using BSA dissolved in saline or adsorbed to alum. These microcapsules providing the controlled release of antigens may be valuable in designing better vaccine formulations.
AB - A model antigen, bovine serum albumin (BSA), was successfully incorporated into microcapsules fabricated from blends of poly(d,l-lactide-co-glycolide) and poly(d,l-lactide). The microcapsules possessed diameters ranging from 10 to 100 μm and exhibited a continuous monophasic release of the protein in-vitro for 3 weeks. They were found to enhance its immunogenicity, thereby potentiating the anti-BSA antibody response following a single subcutaneous injection in mice and rabbits. Enzyme-linked immunosorbent assays demonstrated that the microcapsules provoked high-titre and long-lived immunoglobulin G immune responses over a period of 192 days in mice. When rabbits were immunized by a single subcutaneous injection of BSA-loaded microcapsules, a high level of anti-BSA antibody was still present in the sera obtained at 17 weeks post-injection. The immunization protocol using the BSA-loaded microcapsules was superior to that using BSA dissolved in saline or adsorbed to alum. These microcapsules providing the controlled release of antigens may be valuable in designing better vaccine formulations.
UR - http://www.scopus.com/inward/record.url?scp=0029917690&partnerID=8YFLogxK
U2 - 10.1111/j.2042-7158.1996.tb05872.x
DO - 10.1111/j.2042-7158.1996.tb05872.x
M3 - Article
C2 - 8722491
AN - SCOPUS:0029917690
SN - 0022-3573
VL - 48
SP - 32
EP - 36
JO - Journal of Pharmacy and Pharmacology
JF - Journal of Pharmacy and Pharmacology
IS - 1
ER -